Top Page
Austco Healthcare Limited
(Sydney:AHC)
Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)
Austco Healthcare Limited Business Overview & Revenue Model
Austco Healthcare Limited Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 58.15M | 41.98M | 35.88M | 31.25M | 31.60M | Gross Profit |
| 30.67M | 6.68M | 18.85M | 16.71M | 16.44M | EBIT |
| 5.79M | 1.80M | 2.14M | 2.10M | 2.74M | EBITDA |
| 8.11M | 3.60M | 3.52M | 3.13M | 3.65M | Net Income Common Stockholders |
| 7.08M | 2.26M | 2.33M | 3.42M | 2.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 13.56M | 4.67M | 7.63M | 7.77M | 6.45M | Total Assets |
| 68.70M | 37.85M | 34.03M | 27.18M | 23.09M | Total Debt |
| 1.78M | 524.00K | 979.00K | 1.15M | 892.00K | Net Debt |
| -11.78M | -4.15M | -6.65M | -6.62M | -5.55M | Total Liabilities |
| 24.33M | 12.85M | 10.94M | 7.88M | 6.83M | Stockholders Equity |
| 44.38M | 25.00M | 23.09M | 19.30M | 16.26M |
| Cash Flow | Free Cash Flow | |||
| 7.45M | -1.25M | 315.00K | 1.91M | 1.79M | Operating Cash Flow |
| 11.35M | 320.00K | 1.94M | 3.21M | 3.30M | Investing Cash Flow |
| -11.06M | -1.57M | -1.63M | -1.30M | -1.51M | Financing Cash Flow |
| 8.84M | -1.58M | -312.00K | -474.00K | 2.78M |
Austco Healthcare Limited Technical Analysis
Austco Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$56.12B | 27.94 | 25.23% | 0.81% | 10.54% | 38.69% | |
75 Outperform | AU$107.40M | 10.81 | 23.38% | ― | 63.10% | 290.00% | |
73 Outperform | $4.62B | 25.66 | 6.45% | 2.46% | 16.30% | 1.08% | |
72 Outperform | AU$12.62B | 23.06 | 6.86% | 4.07% | 10.15% | 6.20% | |
72 Outperform | $17.65B | 47.69 | 20.61% | 1.62% | 6.35% | 5.97% | |
64 Neutral | $119.40B | 28.66 | 15.38% | 1.77% | 8.00% | 9.09% | |
53 Neutral | $5.14B | 3.03 | -43.89% | 2.83% | 16.75% | -0.06% |
Austco Healthcare Limited Corporate Events
Austco Healthcare Limited has secured a AUD $2.1 million contract to implement its advanced nurse call platform, Tacera, at the new patient and surgical tower of Toronto Western Hospital, part of the University Health Network. This project, part of a $1 billion investment by Ontario, is expected to enhance healthcare delivery with real-time clinical communication and integration with hospital systems, supporting Austco’s North American growth strategy and reinforcing its position as a leader in innovative healthcare solutions.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has renewed its preferred supplier agreement with a major US healthcare provider, continuing to supply and support its Tacera IP Nurse Call systems across approximately 180 healthcare facilities in over 30 US states. This renewal builds on a previous five-year agreement that generated over A$49 million in revenue and reinforces Austco’s position as a leader in digital nurse call and patient management solutions. The company is also shifting production away from China to mitigate tariff challenges, a move expected to be completed in the next few months.
Austco Healthcare Limited has secured a multi-year, multi-million dollar contract with Angeles Health System in Mexico to supply advanced nurse call and infant protection systems across three major hospitals. This AUD $3.4 million contract will enhance Austco’s presence in the Latin American healthcare market, with revenue recognition expected from FY25 to FY27 and support revenues extending to FY29. The agreement includes comprehensive training and technical support, demonstrating Austco’s commitment to delivering scalable healthcare technology solutions. The project will not be affected by U.S. tariffs due to Austco’s drop-shipping model, ensuring cost predictability and uninterrupted delivery.
Austco Healthcare Limited has announced a strategic acquisition of G&S Technologies, a New Zealand-based provider of integrated communication and security systems for healthcare facilities. This acquisition aligns with Austco’s strategy to expand its direct sales capabilities and enhance its portfolio of solutions, aiming to accelerate growth and improve market penetration. The acquisition is expected to be immediately earnings per share accretive and will enable Austco to engage with common corporate clients across New Zealand and Australia, compete for larger opportunities, and deliver integrated technology solutions. The transaction is set to complete on June 1, 2025, and is anticipated to provide significant revenue synergies.
Austco Healthcare Limited announced that its CEO and Executive Director, Clayton Astles, has sold 500,000 shares due to extraordinary personal circumstances involving medical expenses for a family member. Despite the sale, Mr. Astles remains committed to the company, retaining a shareholding and expressing confidence in Austco’s long-term growth and strategy. The Board supports Mr. Astles’ decision, extending their thoughts to him and his family during this challenging time.
Austco Healthcare Limited has successfully completed the earn-out period for its acquisition of Teknocorp, making a final payment of $799,092 and settling all contingent considerations. The acquisition has bolstered Austco’s revenue and profit growth, enhancing its market strategy in Australia and aligning its services with global operations. The release of 3,888,889 shares from voluntary escrow is also announced, although the company acknowledges a delay in notification due to an administrative oversight. Austco remains committed to transparency and regulatory compliance.
Austco Healthcare Limited’s subsidiary in Canada has secured its largest Software and Maintenance Agreement (SMA) contract, valued at AUD $1.02 million, with West Park Hospital in Toronto. This five-year agreement, starting in April 2025, emphasizes Austco’s strategic focus on expanding recurring software and service revenues, enhancing revenue predictability, and providing ongoing support and upgrades to its customers. The contract underscores the growing demand for Austco’s healthcare communication solutions and strengthens its position in the industry by aligning with its strategic growth initiatives.
Austco Healthcare Limited has reported a record performance in the first half of the fiscal year 2025, driven by successful integration of acquisitions. The company achieved a 62% revenue growth, reaching $36.9 million, and a 150% increase in EBITDA, totaling $5.2 million, which exceeded the top end of their guidance. Additionally, the company saw a 270% growth in NPBT, with profits rising to $3.9 million, and a 15% growth in software and SMA revenues, which reached $4.6 million.
Austco Healthcare Limited announced a change in the director’s interest, with James Brett Francis Burns adjusting his holdings in the company. The transaction involved the acquisition of 172,413 shares indirectly and the disposal of 149,183 shares directly, reflecting a strategic realignment of his investment portfolio. This change signifies a potential shift in the director’s confidence or strategic focus within the company, which could have implications for stakeholders and investors monitoring the company’s governance and market activities.
Austco Healthcare Limited reported a significant increase in its financial performance for the six months ending December 2024, with revenues rising by 62% to $36.9 million and EBITDA soaring by 150% to $5.2 million. This growth was driven by the successful integration of recently acquired businesses, Teknocorp and Amentco, which contributed $11.9 million to the revenue, and strong organic growth in Asia and North America. Despite a slight reduction in gross margins due to the lower margins of the acquired businesses, the company maintained a steady gross margin dollar amount. The increase in software and SMA revenues by 15% to $4.6 million highlights the strategic importance of these segments in Austco’s future growth, as they represent a significant portion of unfilled contracted revenue.
Austco Healthcare Limited reported a significant increase in its financial performance for the half year ended 31 December 2024, with revenue rising by 61.6% compared to the same period in 2023. The company’s net profit after tax surged by 150.1%, highlighting strong operational improvements and effective cost management. This financial growth underscores Austco Healthcare’s enhanced market positioning and potential positive implications for stakeholders.